The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2019. The common things for fund are deals in the range of more than 100 millions dollars.
The standard case for the fund is to invest in rounds with 7 partakers. Despite the Guangzhou Yue Min Investment, startups are often financed by OrbiMed. The meaningful sponsors for the fund in investment in the same round are South China Venture Capital, Pan-Lin Asset Management, OrbiMed.
Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular fund investment industries, there are Alternative Medicine, Health Care. Among the various public portfolio startups of the fund, we may underline Apollomics
| Fund Name | Location |
| Accelerasia Ventures | Central Region, Singapore, Singapore |
| Avetta | California, Irvine, United States |
| Calega | - |
| Chengshi Dingxin | - |
| Dickey Revocable Living Trust | - |
| Funcity Capital | China, Hangzhou, Zhejiang |
| Gooray Tax | Chengguan District, China, Lhasa |
| Hollencrest Capital Management | California, Newport Beach, United States |
| Lucros Investment | - |
| Shanghai Rizhang Investment Management | China, Shanghai |
| Sprout Fund LP | Alberta, Canada, Edmonton |
| St. Luke's University Health Network | Bethlehem, Pennsylvania, United States |
| Stonehenge Growth Equity | Florida, Tampa, United States |
| Sulphur Creek Ventures | California, St. Helena, United States |
| Ulupono Initiative | Hawaii, Honolulu, United States |
| VGangels | - |
| Zhengming Modern Logistics | China, Qingpu, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Centrymed | 09 Feb 2022 | Hangzhou, Zhejiang, China | |||
Iluvatar CoreX | $185M | 01 Mar 2021 | Xuanwu District, Jiangsu, China | ||
Apollomics | $100M | 08 Jan 2019 | California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Centrymed | 09 Feb 2022 | Hangzhou, Zhejiang, China | |||
Iluvatar CoreX | $185M | 01 Mar 2021 | Xuanwu District, Jiangsu, China | ||
Apollomics | $100M | 08 Jan 2019 | California, United States |
